Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Monoacetylcystine SCHEMBL468826 | 1.00 | MAPT (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL20816351 | 1.00 | MAPT (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL468824 | 1.00 | MAPT (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL29438781 | 1.00 | MAPT (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL6368208 | 0.98 | MAPT (0.47) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL31253425 | 0.98 | MAPT (0.47) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL6368194 | 0.98 | MAPT (0.47) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Monoacetylcystine SCHEMBL26134149 | 0.97 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL20839964 | 0.90 | MAPT (0.46) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL17749411 | 0.90 | NOS2 (0.44) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600953-B2 | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-04-14 | — | — | US | claimed |
| US-12351678-B2 | Process for preparing stabilized aliphatic polyester, and compositions obtained therewith | TOTALENERGIES CORBION B.V. (NL) | 2025-07-08 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-12245998-B2 | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis | NACUITY PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | claimed |
| CN-119156343-A | Peptide-carrying carrier system and use thereof | 周美吟 | 2024-12-17 | — | — | CN | claimed |
| US-12121536-B2 | Strontium based compositions and formulations for pain, pruritus, and inflammation | GALLEON LABS LLC (US) | 2024-10-22 | — | — | US | claimed |
| EP-4438014-A2 | IMPROVING PULMONARY AIRFLOW | Apreo Health, Inc. (US) | 2024-10-02 | — | — | EP | claimed |
| CN-114740119-B | Method for detecting 11 components in compound amino acid injection | 江苏大学 | 2024-03-12 | — | — | CN | claimed |
| EP-4172275-B1 | TIO2-FREE PIGMENT | SUN CHEMICAL CORP (US) | 2024-02-07 | — | — | EP | claimed |
| EP-3976705-B1 | PROCESS FOR PREPARING STABILIZED ALIPHATIC POLYESTER, AND COMPOSITIONS OBTAINED THEREWITH | TOTALENERGIES CORBION B V (NL) | 2024-01-10 | — | — | EP | claimed |
| US-6159352-A | Process for the electrochemical synthesis of N-acetylcysteine from cystine | UNIVERSIDAD DE ALICANTE (ES) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| EP-0905282-B1 | PROCESS FOR THE ELECTROCHEMICAL SYNTHESIS OF N-ACETYLCYSTEINE FROM CYSTINE | UNIV ALICANTE (ES) | 2000-01-26 | — | — | EP | claimed |
| US-6017959-A | AN IMMUNOMODULATOR FOR TREATING CHRONIC BRONCHITIS, A MALIGNANT DISEASE, A CHRONIC INFECTIONS, A CHRONIC HEPATITIS B OR C VIRAL INFECTION | ASTRA AKTIEBOLAG (SE) | 2000-01-25 | — | — | US | claimed |
| EP-0905282-A1 | PROCESS FOR THE ELECTROCHEMICAL SYNTHESIS OF N-ACETYLCYSTEINE FROM CYSTINE | UNIVERSIDAD DE ALICANTE (ES) | 1999-03-31 | — | — | EP | claimed |
| EP-0875244-A2 | Cosmetically accceptable microstructured compositions | Ciba SC Holding AG (CH) | 1998-11-04 | — | — | EP | claimed |
| EP-0538193-B1 | Condensed cycloaliphatir-amidino-hydrazon salts as S-adenosylmethionin decarboxylase inhibitors | CIBA GEIGY AG (CH) | 1996-12-04 | — | — | EP | claimed |
| US-5415870-A | Layers of acid, alkali carbonate and alkali metal salt of acid | Gergely, Gerhard (AT) | 1995-05-16 | — | — | US | claimed |
| US-4372874-A | Stabilization of hydrolysis prone labile organic reagents in liquid media | MEDICAL ANALYSIS SYSTEMS, INC. | 1983-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600953-B2 | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | BMP4, DSP, WNT3A | MAPT 3267/4885KDM4E 872/4885THRB 464/4885 |
| US-12245998-B2 | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis | AADAC, GCLC, CFTR | MAPT 4776/4885KDM4E 4748/4885THRB 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.